Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Analyst Ratings
This is a summary of recent recommendations for Xenetic Biosciences and Nektar Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Nektar Therapeutics | 1 | 2 | 9 | 1 | 2.77 |
Nektar Therapeutics has a consensus target price of $138.50, suggesting a potential upside of 133.24%. Given Nektar Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Xenetic Biosciences.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $2.98 million | 1.90 | -$2.68 million | ($1.16) | -2.13 |
| Nektar Therapeutics | $54.59 million | 37.14 | -$164.08 million | ($6.70) | -8.86 |
Xenetic Biosciences has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Xenetic Biosciences has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Profitability
This table compares Xenetic Biosciences and Nektar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
| Nektar Therapeutics | -287.84% | -37.87% | -25.67% |
Summary
Nektar Therapeutics beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
